Antillón, M., Bilcke, J., Paltiel, A. D., & Pitzer, V. E. (2017). Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low-and middle-income settings. Vaccine, 35(27), 3506–3514. https://doi.org/10.1016/j.vaccine.2017.05.001
BATOOL, R. (n.d.). Impact Assessment of Typhoid Conjugate Vaccine in South Asian Slums. https://trepo.tuni.fi/bitstream/handle/10024/224785/978-952-03-3847-3.pdf?sequence=2
Emary, K., Bentsi-Enchill, A. D., Giersing, B. K., Gordon, M., Dale, H., Chirwa, E. B., Johnston, P., MacLennan, C. A., Kariuki, S., & Excler, J.-L. (2025). Landscape analysis of invasive non-typhoidal salmonella (iNTS) disease and iNTS vaccine use case and demand: Report of a WHO expert consultation. Vaccine, 55, 127008. ttps://doi.org/10.1016/j.vaccine.2025.127008
Gloeck, N. R., Leong, T. D., Mthethwa, M., Iwu-Jaja, C. J., Katoto, P. D., Wiysonge, C. S., & Kredo, T. (2025). Typhoid conjugate vaccines for preventing typhoid fever (enteric fever). The Cochrane Database of Systematic Reviews, 2025(5), CD015746. oi: 10.1002/14651858.CD015746.pub2
Ibarz-Pavon, A. B., Bielsky, M.-C., Bose, R., Cavaleri, M., Crump, J. A., Hombach, J., Kaslow, D. C., Khaman, F., MacLennan, C. A., & Mehring-LeDoare, K. (2025). Consultation report–considerations for a regulatory pathway for bivalent Salmonella Typhi/Paratyphi A vaccines for use in endemic countries. Vaccine, 56, 127189. https://doi.org/10.1016/j.vaccine.2025.127189
Meiring, J. E., Laurens, M. B., Patel, P., Patel, P., Misiri, T., Simiyu, K., Mwakiseghile, F., Tracy, J. K., Masesa, C., & Liang, Y. (2019). Typhoid Vaccine Acceleration Consortium Malawi: A phase III, randomized, double-blind, controlled trial of the clinical efficacy of typhoid conjugate vaccine among children in Blantyre, Malawi. Clinical Infectious Diseases, 68(Supplement_2), S50–S58. https://doi.org/10.1093/cid/ciy1103
Mogasale, V. V., Sinha, A., John, J., Farooqui, H. H., Ray, A., Chantler, T., Mogasale, V., Dhoubhadel, B. G., Edmunds, W. J., & Clark, A. (2024a). Research priorities to support typhoid conjugate vaccine decision-making in India: Evidence assessment and stakeholder survey. BMJ Public Health,doi:10.1136/ bmjph-2024-001089 2(2).
Mogasale, V. V., Sinha, A., John, J., Farooqui, H. H., Ray, A., Chantler, T., Mogasale, V., Dhoubhadel, B. G., Edmunds, W. J., & Clark, A. (2024b). Typhoid conjugate vaccine implementation in India: A review of supportive evidence. Vaccine: X, 100568. https://doi.org/10.1016/j.jvacx.2024.100568
Mohan, V. K., Varanasi, V., Singh, A., Pasetti, M. F., Levine, M. M., Venkatesan, R., & Ella, K. M. (2015). Safety and immunogenicity of a Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: A multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clinical Infectious Diseases, 61(3), 393–402. https://doi.org/10.1093/cid/civ295
Soble, A., Ko, M., Gilchrist, S., Malvolti, S., Hasso-Agopsowicz, M., Giersing, B., Amorij, J.-P., Jarrahian, C., El Sheikh, F., & Menozzi-Arnaud, M. (2024). A review of potential use cases for measles-rubella, measles-mumps-rubella, and typhoid-conjugate vaccines presented on microarray patches. Vaccine, 42(6), 1230–1246. https://doi.org/10.1016/j.vaccine.2023.12.047